Evidence map›Paper›PMID 35410363›Full record

ArticleTrials2022

Bronchiectasis - Exercise as Therapy (BREATH): rationale and study protocol for a multi-center randomized controlled trial.

Taryn Jones, Kerry-Ann F O'Grady, Vikas Goyal, Ian B Masters, Gabrielle McCallum, Christopher Drovandi, Thomas Lung, Emmah Baque, Denise S K Brookes, Caroline O Terranova and 2 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Taryn JonesQueensland University of Technology, Brisbane, QLD, Australia.
Kerry-Ann F O'GradyQueensland University of Technology, Brisbane, QLD, Australia.
Vikas GoyalQueensland Children's Hospital, Brisbane, QLD, Australia.
Ian B MastersQueensland Children's Hospital, Brisbane, QLD, Australia.
Gabrielle McCallumMenzies School of Health Research, Darwin, NT, Australia.
Christopher DrovandiQueensland University of Technology, Brisbane, QLD, Australia.
Thomas LungGeorge Institute for Global Health, Sydney, NSW, Australia.
Emmah BaqueGriffith University, Brisbane, QLD, Australia.
Denise S K BrookesQueensland University of Technology, Brisbane, QLD, Australia.
Caroline O TerranovaQueensland University of Technology, Brisbane, QLD, Australia.
Anne B ChangQueensland University of Technology, Brisbane, QLD, Australia.
Stewart G TrostQueensland University of Technology, Brisbane, QLD, Australia. s.trost@qut.edu.au.ORCID http://orcid.org/0000-0001-9587-3944
Queensland University of Technology · AUChildren's Health Queensland Hospital and Health Service · AUGriffith University · AUMenzies School of Health Research · AUThe George Institute for Global Health · AUThe University of Queensland · AU

Funding

national health and medical research council 1160613
6 · The paper itself

Abstract

backgroundGlobally, bronchiectasis (BE) unrelated to cystic fibrosis (CF) is recognized as a major cause of respiratory morbidity, mortality, and healthcare utilization. Children with BE regularly experience exacerbations of their condition resulting in frequent hospitalizations and decreased health-related quality of life (HR-QoL). Guidelines for the treatment and management of BE call for regular exercise as a means of improving aerobic fitness and HR-QoL. Moreover, research in adults with BE has shown that exercise can reduce the frequency of exacerbations, a potent predictor of future lung function decline and respiratory morbidity. Yet, to date, the health benefits resulting from therapeutic exercise have not been investigated in children with BE. The BREATH, Bronchiectasis - Exercise as Therapy, trial will test the efficacy of a novel 8-week, play-based therapeutic exercise program to reduce the frequency of acute exacerbations over 12 months in children with BE (aged ≥ 4 and < 13 years). Secondary aims are to determine the cost-effectiveness of the intervention and assess the program's impact on aerobic fitness, fundamental movement skill (FMS) proficiency, habitual physical activity, HR-QoL, and lung function.

methodsThis multi-center, observer-blinded, parallel-group (1:1 allocation), randomized controlled trial (RCT) will be conducted at three sites. One hundred and seventy-four children ≥ 4 and < 13 years of age with BE will be randomized to a developmentally appropriate, play-based therapeutic exercise program (eight, 60-min weekly sessions, supplemented by a home-based program) or usual care. After completing the baseline assessments, the number of exacerbations and secondary outcomes will be assessed immediately post-intervention, after 6 months of follow-up, and after 12 months of follow-up. Monthly, parental contact and medical review will document acute respiratory exacerbations and parameters for cost-effectiveness outcomes. DISCUSSION: The BREATH trial is the first fully powered RCT to test the effects of a therapeutic exercise on exacerbation frequency, fitness, movement competence, and HR-QoL in children with bronchiectasis. By implementing a developmentally appropriate, play-based exercise program tailored to the individual needs of children with bronchiectasis, the results have the potential for a major paradigm shift in the way in which therapeutic exercise is prescribed and implemented in children with chronic respiratory conditions. The exercise program can be readily translated. It does not require expensive equipment and can be delivered in a variety of settings, including the participant's home. The program has strong potential for translation to other pediatric patient groups with similar needs for exercise therapy, including those with obesity, childhood cancers, and neurological conditions such as cerebral palsy.

trial registrationAustralian and New Zealand Clinical Trials Register (ANZCTR) ACTRN12619001008112.

Indexed as

BronchiectasisAdolescentAdultAustraliaChildDisease ProgressionExerciseExercise TherapyHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicBronchiectasisExacerbationExercisePediatricPhysical activityRandomized Controlled trial

Identifiers

PMID35410363
PMCPMC8996596
OpenAlexW4226417360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.